Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
1.
Eur Rev Med Pharmacol Sci ; 26(10): 3760-3770, 2022 05.
Article in English | MEDLINE | ID: covidwho-1876425

ABSTRACT

OBJECTIVE: This meta-analysis aims to assess the susceptibility to and clinical outcomes of COVID-19 in autoimmune inflammatory rheumatic disease (AIRD) and following AIRD drug use. MATERIALS AND METHODS: We included observational and case-controlled studies assessing susceptibility and clinical outcomes of COVID-19 in patients with AIRD as well as the clinical outcomes of COVID-19 with or without use of steroids and conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). RESULTS: Meta-analysis including three studies showed that patients with AIRD are not more susceptible to COVID-19 compared to patients without AIRD or the general population (OR: 1.11, 95% CI: 0.58 to 2.14). Incidence of severe outcomes of COVID-19 (OR: 1.34, 95% CI: 0.76 to 2.35) and COVID-19 related death (OR: 1.21, 95% CI: 0.68 to 2.16) also did not show significant difference. The clinical outcomes of COVID-19 among AIRD patients with and without csDMARD or steroid showed that both use of steroid (OR: 1.69, 95% CI: 0.96 to 2.98) or csDMARD (OR: 1.35, 95% CI: 0.63 to 3.08) had no effect on clinical outcomes of COVID-19. CONCLUSIONS: AIRD does not increase susceptibility to COVID-19, not affecting the clinical outcome of COVID-19. Similarly, the use of steroids or csDMARDs for AIRD does not worsen the clinical outcome.


Subject(s)
Antirheumatic Agents , Autoimmune Diseases , COVID-19 , Rheumatic Diseases , Antirheumatic Agents/therapeutic use , COVID-19/drug therapy , Humans , Incidence , Rheumatic Diseases/drug therapy , Rheumatic Diseases/epidemiology
2.
Journal of the Korean Society of Clothing and Textiles ; 46(1):116-131, 2022.
Article in English | Scopus | ID: covidwho-1847602

ABSTRACT

This study used text mining to analyze big data to understand consumers’ demand for and perceptions of fashion masks. Based on the text-mining analysis results, a survey was conducted with those living in Korea to investigate the influence of consumers’ mask selection criteria on mask brand awareness and purchase intention for fashion masks. “Fashion mask” and “functional mask” were used as the keywords in a text-mining analysis, and an online survey of 242 respondents was conducted. The analysis results were as follows: First, the text-mining analysis extracted commonly appearing words that had a high frequency and TF-IDF, such as “COVID-19,” “fashion,” “celebrity,” “antibacterial,” and “filter.” This confirmed that during the COVID-19 pandemic, consumers have demanded masks that are both functional and fashionable. Second, among consumers’ mask selection criteria, trend and design had positive effects on face-mask brand awareness. Third, face-mask brand awareness had a positive effect on the purchase intention for both brand and fashion masks, and the purchase intention for brand masks had a positive effect on the purchase intention for fashion masks. © 2022. The Korean Society of Clothing and Textiles. All rights reserved

3.
9th International Conference on Robot Intelligence Technology and Applications, RiTA 2021 ; 429 LNNS:201-209, 2022.
Article in English | Scopus | ID: covidwho-1802617

ABSTRACT

This research was carried out to provide an indoor service platform for employees with special needs. Disabled people have more energy/cost to adjust to the new work environment generated by COVID-19 than people without disabilities. Low job proficiency increases the number of customers waiting in the shop, which can reduce the café’s recycling rate and raise the danger of group infection. To resolve these issues, innovative technology must be used to prevent COVID-19 and improve employee health security for persons with disabilities. As a response to these issues, this paper proposes how to design an interactive delivery robot. The robot interacts with the human user via verbal expressions, such as explaining the destination using a speaker and a touch sensor and providing delivery services using a Lidar sensor and two actuators. The robot’s ability to go from the cafe to the target location, deliver the drink, and then return to the cafe to repeat the operation was proven as a consequence of the real design and implementation. We used ROS to bring those functions together on a single platform. This research is anticipated to revive the COVID-19 period, which has seen mutual communication go away, as well as contribute to economic restoration. Furthermore, I believe that given its aesthetic and practical benefits, it will be feasible to alleviate the job uncertainty that occurs in stores that employ individuals with impairments. © 2022, The Author(s), under exclusive license to Springer Nature Switzerland AG.

4.
2021 IEEE International Conference on Bioinformatics and Biomedicine, BIBM 2021 ; : 1339-1342, 2021.
Article in English | Scopus | ID: covidwho-1722877

ABSTRACT

Coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread around the world with high mortality rates. Since this virus constantly mutating rapidly, it causes different kinds of variants such as the Delta Plus variant, and this variant even dominated the original Delta variant. Thus, designing a new primer-probe set is required to cope with the new variant effectively. However, the existing primer-probe set design tools are also effective in designing for a given sequence, but it is difficult to consider all variants or off-target. Here, we introduce a web-based method for designing and validating primer-probe sets for SARS-CoV-2. Through the web server we built, a user could get results of the binding site matching, homology tests, and variant coverage calculation of the primer-probe set they designed. Moreover, a user also could find the primer-probe sets which bind as many SARS-CoV-2 variants as possible by using the user-input FASTA sequence. We believe that our web service would help researchers by reducing the difficulty of designing primers and probes of SARS-CoV-2. © 2021 IEEE.

5.
European Review for Medical and Pharmacological Sciences ; 25(23):7390-7397, 2021.
Article in English | Web of Science | ID: covidwho-1576450

ABSTRACT

OBJECTIVE: Although remdesivir (GS-5734) has recently demonstrated clinical benefits against the pandemic outbreak of coronavirus disease 2019 (COVID-19), neuropsychological adverse reactions (ADRs) remain to be examined in real-world settings. Therefore, we aimed to identify and characterize the neuropsychological ADRs associated with remdesivir use. MATERIALS AND METHODS: We obtained data for this international pharmacovigilance cohort study from individual case safety reports (ICSRs) in a World Health Organization database (VigiBase) from the first report on remdesivir on February 17, 2020, until August 30, 2020 (n=1,403,532). ADRs reported to be relevant to remdesivir were compared with the full database by using a Bayesian neural network method to calculate the information component (IC). RESULTS: A total of 2,107 reported cases of neuropsychological ADRs suspected to be associated with remdesivir were identified from among all ICSRs in the database during the observation period. Although 108 neuropsychological ADRs (64 neurologic events and 44 psychologic events) were reported in association with the medication, no statistically significant pharmacovigilance signal could be detected;the ICO25 value was negative for all of the neuropsychological dysfunctions (anxiety [n=13, 0.62%], seizures [n=12, 0.57%], lethargy [n=6, 0.28%], agitation [n=5, 0.25%], cerebral infarction [n=3, 0.14%]. ischemic stroke [n=3, 0.14%], and hemiparesis [n=3, 0.14%]). CONCLUSIONS: Our study demonstrates that remdesivir, a novel drug applied to the treatment of COVID-19, does not have a significant association with adverse neurologic or psychiatric reactions in the real-world setting.

6.
Blood ; 138:184, 2021.
Article in English | EMBASE | ID: covidwho-1582407

ABSTRACT

Background: Early reports suggested that cancer patients have a 1.7-fold increased risk of contracting SARS-CoV-2 and higher rates of severe events and mortality compared with general population. Patients with hematologic malignancies may have worse COVID-19 outcomes, due to an impaired humoral immune response from their underlying malignancy and concurrent anticancer therapy. In this multi-center, retrospective, observational study, we evaluate the associations of COVID-19 outcomes with patient and lymphoma disease characteristics. Methods: EMRs at 10 study centers across the USA identified 519 patients with a diagnosis of lymphoma, CLL, or other lymphoid malignancies, who had a documented positive result of SARS-CoV-2 PCR or nucleocapsid antibody testing. Descriptive statistics were used to summarize the demographic and clinical characteristics. Logistic regression was used to evaluate the associations of individual characteristics with COVID-19 outcomes, adjusted for center (NYU vs. other). The interactions between each of the variables was also included in these models;since the interactions were generally small and non-significant, only the main effect of center was included. Two-sided p-values ≤0.05 were considered significant;there were no adjustments for multiple variables or endpoints. Each analysis was based on complete data for that analysis. Results: Tables 1 and 2 provide demographic and clinical characteristics, respectively, of the 519 patients. The mean age was 61.9 years, with 296 (57%) male and 374 (72%) white patients. NYU had the largest cohort (318 patients), with the remaining centers contributing a range of 3 to 69 patients (median 14). Logistic regression models for the association of each COVID-19 outcome with individual clinical and patient characteristics included adjustments for the center (NYU/other). While center effects were statistically significant, center by covariate interaction effects were not and are not included in the final models. The odds ratio (OR) estimates and p-values for each patient and CLL/lymphoma clinical variable are shown in Tables 3 and 4, respectively. The risks of experiencing a severe event, death, and hospital admission increased with age;for each 10 years of age increase, the ORs were 1.58 for experiencing severe events, 1.78 for death, and 1.65 for hospital admission. The risks of poor outcome were higher in males than in females (OR 1.93 for severe events, 1.85 for death, and 1.47 for hospital admission). Patients with Charlson Comorbidity Index (CCI) >5 had a higher risk of severe events (OR 2.46), mortality (3.30) and hospital admission (2.73) compared to patients with CCI ≤5. Compared to patients with HL, patients with aggressive NHL had a higher risk of severe events (OR 4.05), mortality (4.68) and hospital admission (4.65). Patients with CLL similarly had a higher risk of severe events (OR 4.64), mortality (4.65) and hospital admission (5.93) compared to HL patients. Patients with indolent NHL had a higher risk of hospital admission (OR 3.95) but not a higher risk of mortality compared to HL. Patients in remission at the time of COVID-19 diagnosis had a lower risk of severe events (OR 0.42), mortality (0.36) and hospital admission (0.40) relative to those who were not in remission. Patients who received cytotoxic chemotherapy within 28 days of their COVID-19 diagnosis had a higher risk of severe events (OR 2.54), mortality (2.79), and hospital admission (2.31). Patients who received an anti-CD20 monoclonal antibody within 6 months of COVID-19 diagnosis had a higher risk of severe events (OR 2.60), mortality (2.17) and hospital admission (3.28). Conclusions: In addition to demographic and comorbidity risk factors identified in previous studies, our study shows that patients with aggressive NHL and CLL, or patients who have received recent cytotoxic chemotherapy or anti-CD20 mAB, may be at risk for poor COVID-19 outcome. The difference in risk between NHL and HL patients is likely associated with young age of HL patients but may also be related o differences in underlying innate and adaptive immune defects. Patients at high risk for poor outcome should be a priority for studies of monoclonal antibody prophylaxis. If defects in humoral immunity are at the root of poor outcome, this may be compounded by poor response to vaccination. Multivariate analysis of this data will be completed in advance of the meeting. [Formula presented] Disclosures: Olszewski: Celldex Therapeutics: Research Funding;PrecisionBio: Research Funding;TG Therapeutics: Research Funding;Acrotech Pharma: Research Funding;Genentech, Inc.: Research Funding;Genmab: Research Funding. Barta: Daiichi Sankyo: Honoraria;Seagen: Honoraria;Acrotech: Honoraria;Kyowa Kirin: Honoraria. Hernandez-Ilizaliturri: AbbVie: Other: Advisory Boards;Incyte: Other: Advisory Boards;Celgene: Other: Advisory Boards;BMS: Other: Advisory Boards;Pharmacyclics: Other: Advisory Boards;Amgen: Other: Advisory Boards;Kite: Other: Advisory Boards;Gilead: Other: Advisory Boards;Epyzime: Other: Advisory Boards. Leslie: Janssen: Consultancy, Speakers Bureau;Merck: Consultancy;Abbvie: Consultancy, Honoraria;Epizyme: Consultancy, Honoraria, Speakers Bureau;PCYC/Janssen: Consultancy, Honoraria, Speakers Bureau;Seagen: Consultancy, Honoraria, Speakers Bureau;TG Therapeutics: Consultancy, Honoraria, Speakers Bureau;Celgene/BMS: Consultancy, Honoraria, Speakers Bureau;Kite, a Gilead Company: Consultancy, Honoraria, Speakers Bureau;ADC Therapeutics: Consultancy;BeiGene: Consultancy, Honoraria, Speakers Bureau;Karyopharm Therapeutics: Honoraria, Speakers Bureau;AstraZeneca: Consultancy, Honoraria, Speakers Bureau;Pharmacyclics: Consultancy, Honoraria, Speakers Bureau. Diefenbach: Bristol-Myers Squibb: Consultancy, Honoraria, Research Funding;Merck Sharp & Dohme: Consultancy, Honoraria, Research Funding;Morphosys: Consultancy, Honoraria, Research Funding;Genentech, Inc./ F. Hoffmann-La Roche Ltd: Consultancy, Honoraria, Research Funding;Perlmutter Cancer Center at NYU Langone Health: Current Employment;Incyte: Research Funding;AbbVie: Research Funding;Trillium: Research Funding;IGM Biosciences: Research Funding;IMab: Research Funding;Janssen: Consultancy, Honoraria, Research Funding;Gilead: Current equity holder in publicly-traded company;MEI: Consultancy, Research Funding;Celgene: Research Funding;Seattle Genetics: Consultancy, Honoraria, Research Funding.

7.
Research and Practice in Thrombosis and Haemostasis ; 5(SUPPL 2), 2021.
Article in English | EMBASE | ID: covidwho-1509033

ABSTRACT

Background : SARS-CoV-2 was reported to affect hemostasis, and thrombosis laboratory indices but its effect on lupus anticoagulant remains controversial. Aims : The purpose of this study is to learn more about the properties of lupus anticoagulant in patients with COVID-19 in Korea. Methods : We retrospectively searched for COVID-19 confirmed patients at the Asan Medical Center from March 2020 to February 2021. Medical chart review was conducted to collect their clinical information and hematology laboratory data. Among 142 confirmed patients, 67 patients with lupus anticoagulant testing were included to determine the differences in laboratory indices, especially LA. Results : Most of the patients in our study had mild clinical courses. Lupus anticoagulant was identified in 67.8% of survivors and 25.0% of deaths. In the LA confirmatory test, 97.5% DRVVT and 10.0% SCT positivity were found. Among 40 LA-positive patients, 13 patients were lost for follow up, and 12 patients were unable to determine time-lapse until negative transition of LA. Of the 15 patients who had serial follow-up LA test data, 10 patients (66.7%) were found with rapid disappearance within 6 weeks and 4 case (26.7%) of negative conversion within 6 to 12 weeks. Most of cases (93.3%) disappearance of LA less than 12 weeks. There were no other antiphospholipid syndrome-related antibodies, such as anti-cardiolipin antibodies or anti-beta-2-gylcoprotein, except for 2 of the 40 patients who were LA positive. FIGURE 1 Classification of COVID-19 patients based on Lupus anticoagulant test TABLE 1 Hematology laboratory parameters of COVID-19 patients based on Lupus anticoagulant test Conclusions : As previously reported, LA was found in a high proportion of COVID-19 patients. This is the first study to confirm that the proportion of LA positivity (67.8%) is high in Korean COVID patients. Most LA positivity disappeared within 12 weeks (93.3%). The clinical significance of high LA positive rates and rapid negative transitions in COVID-19 patients is currently unknown, but needs confirmation.

9.
Journal of Microbiology Immunology and Infection ; 54(2):253-260, 2021.
Article in English | Web of Science | ID: covidwho-1237775

ABSTRACT

Background/Purpose: Transplant recipients are vulnerable to life-threatening community-acquired respiratory viruses (CA-RVs) infection (CA-RVI). Even if non-transplant critically ill patients in intensive care unit (ICU) have serious CA-RVI, comparison between these groups remains unclear. We aimed to evaluate clinical characteristics and mortality of CARVI except seasonal influenza A/B in transplant recipients and non-transplant critically ill patients in ICU. Methods: We collected 37,777 CA-RVs multiplex real-time reverse transcription-polymerase chain reaction test results of individuals aged >18 years from November 2012 to November 2017. The CA-RVs tests included adenovirus, coronavirus 229E/NL63/OC43, human bocavirus, human metapneumovirus, parainfluenza virus 1/2/3, rhinovirus, and respiratory syncytial virus A/B. Results: We found 286 CA-RVI cases, including 85 solid organ transplantation recipients (G1), 61 hematopoietic stem cell transplantation recipients (G2), and 140 non-transplant critically ill patients in ICU (G3), excluding those with repeated isolation within 30 days. Adenovirus positive rate and infection cases were most prominent in G2 (p < 0.001). The median time interval between transplantation and CA-RVI was 30 and 20 months in G1 and G2, respectively. All-cause in hospital mortality was significantly higher in G3 than in G1 or G2 (51.4% vs. 28.2% or 39.3%, p Z 0.002, respectively). The mechanical ventilation (MV) was the independent risk factor associated with all-cause in-hospital mortality in all three groups (hazard ratio, 3.37, 95% confidence interval, 2.04e5.56, p < 0.001). Conclusions: This study highlights the importance of CA-RVs diagnosis in transplant recipients even in long-term posttransplant period, and in non-transplant critically ill patients in ICU with MV. Copyright & ordf;2019, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/bync-nd/4.0/).

10.
Microorganisms ; 9(4):03, 2021.
Article in English | MEDLINE | ID: covidwho-1210143

ABSTRACT

The outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), results in serious chaos all over the world. In addition to the available vaccines, the development of treatments to cure COVID-19 should be done quickly. One of the fastest strategies is to use a drug-repurposing approach. To provide COVID-19 patients with useful information about medicines currently being used in clinical trials, twenty-four compounds, including antiviral agents, were selected and assayed. These compounds were applied to verify the inhibitory activity for the protein function of 3CLpros (main proteases) of SARS-CoV and SARS-CoV-2. Among them, viral reverse-transcriptase inhibitors abacavir and tenofovir revealed a good inhibitory effect on both 3CLpros. Intriguingly, sildenafil, a cGMP-specific phosphodiesterase type 5 inhibitor also showed significant inhibitory function against them. The in silico docking study suggests that the active-site residues located in the S1 and S2 sites play key roles in the interactions with the inhibitors. The result indicates that 3CLpros are promising targets to cope with SAR-CoV-2 and its variants. The information can be helpful to design treatments to cure patients with COVID-19.

11.
Eur Rev Med Pharmacol Sci ; 24(24): 13089-13097, 2020 12.
Article in English | MEDLINE | ID: covidwho-1000855

ABSTRACT

OBJECTIVE: Recently, two influential articles that reported the association of (hydroxy)chloroquine or angiotensin converting enzyme (ACE) inhibitors and coronavirus disease 2019 (COVID-19) mortality were retracted due to significant methodological issues. Therefore, we aimed to analyze the same clinical issues through an improved research method and to find out the differences from the retracted papers. We systematically reviewed pre-existing literature, and compared the results with those of the retracted papers to gain a novel insight. MATERIALS AND METHODS: We extracted common risk factors identified in two retracted papers, and conducted relevant publication search until June 26, 2020 in PubMed. Then, we analyzed the risk factors for COVID-19 mortality and compared them to those of the retracted papers. RESULTS: Our systematic review demonstrated that most demographic and clinical risk factors for COVID-19 mortality were similar to those of the retracted papers. However, while the retracted paper indicated that both (hydroxy)chloroquine monotherapy and combination therapy with macrolide were associated with higher risk of mortality, our study showed that only combination therapy of hydroxychloroquine and macrolide was associated with higher risk of mortality (odds ratio 2.33; 95% confidence interval 1.63-3.34). In addition, our study demonstrated that use of ACE inhibitors or angiotensin receptor blockers (ARBs) was associated with reduced risk of mortality (0.77; 0.65-0.91). CONCLUSIONS: When analyzing the same clinical issues with the two retracted papers through a systematic review of randomized controlled trials and relevant cohort studies, we found out that (hydroxy)chloroquine monotherapy was not associated with higher risk of mortality, and that the use of ACE inhibitors or ARBs was associated with reduced risk of mortality in COVID-19 patients.


Subject(s)
Angiotensin Receptor Antagonists/therapeutic use , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , COVID-19/mortality , Enzyme Inhibitors/therapeutic use , Hydroxychloroquine/therapeutic use , Retraction of Publication as Topic , Age Factors , /statistics & numerical data , COVID-19/drug therapy , COVID-19/epidemiology , COVID-19/immunology , Coronary Artery Disease/epidemiology , Databases, Factual , Diabetes Mellitus/epidemiology , Drug Therapy, Combination , Heart Failure/epidemiology , Humans , Hypertension/epidemiology , Immunocompromised Host/immunology , Information Dissemination , Macrolides/therapeutic use , Obesity/epidemiology , Organ Dysfunction Scores , Protective Factors , Pulmonary Disease, Chronic Obstructive/epidemiology , Randomized Controlled Trials as Topic , Risk Factors , SARS-CoV-2 , Severity of Illness Index , Sex Factors , Smoking/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL